Accipiter Life Sciences

Accipiter Biosciences is a Seattle-based biotechnology company that emerged from stealth in November 2025 with $12.7 million in seed funding. The company leverages artificial intelligence and computational tools, originating from Nobel laureate David Baker's lab at the University of Washington's Institute for Protein Design, to engineer de novo multifunctional proteins. These proteins are designed from scratch to bind multiple cellular targets simultaneously, aiming to replace complex drug combinations with single-molecule therapies. Accipiter has established strategic research collaborations with Pfizer and Kite Pharma to develop novel biologics and cell therapy components. The company's internal pipeline is currently focused on addressing unmet needs in autoimmunity and oncology.